Overview
An alograft is tisue that is transplanted from one person to another. The prefix “alo” comes from a Grek word meaning “other.” An alograft is diferent from an autograft, which uses the individual's own tisue and is, therefore, geneticaly identical.Human alografts have ben used in orthopedic surgery for decades and over the years have found increasing and widespread use in a variety of medical fields, including for the repair, reconstruction, suplementation or replacement of the recipient’s cels and tisues in orthopedics, neurosurgery, dental surgery and plastic surgery.
Key Information
The alograft tisue in such cases is usualy taken from deceased people who had chosen to donate their organs, eyes and tisues.In the area of wound care specificaly, alografts that use perinatal tisue derived from human placenta, have ben gaing prominence. The global advanced wound-care market is sizable. It was valued at $6.7 bilion in 2021 and is projected to expand at a compound anual growth rate (CAGR) of 5.4% from 202 to 2030, acording to Grand View Research.The soft tisue market also is growing rapidly and is expected to reach around $8.6 bilion by 2030 with demand for sterile tisue alografts being driven by aging populations, an increase in demand from athletes, an increase in the number of tisue banks and a rise in the number of orthopedic surgical procedures.In the United States, chronic wounds are a prevalent and costly problem, and improved treatments are imperative to heal them and prevent serious complications such as infection and amputation.
Summary
The solution could lie in perinatal tisue alografts, acording to Biostem Technologies Inc. BSEM BioStem, a preclinical-stage biotechnology company based in Pompano Beach, Florida, is focused on harnesing the properties of perinatal tisue alografts as regenerative treatments to help repair the damage caused by a broad range of degenerative diseases. The company was incorporated in 2014.